Mental health is not just depression, schizophrenia, a mood disorder, anxiety; it has all of the things. We are trying to ...

Esketamine monotherapy demonstrated beneficial antidepressant effects at multiple doses for patients with treatment-resistant depression, according to results of a phase 4 randomized trial published ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Spravato nasal spray, also known as esketamine, can now be used to treat depression in adults with treatment-resistant depression.

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson ...

Esketamine monotherapy was found to significantly improve depressive symptoms in patients with treatment-resistant depression. Johnson & Johnson is seeking to expand the approval of Spravato ...

Esketamine is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression.

The trial, of nearly 700 people with treatment-resistant depression, found that esketamine nasal spray was more effective at sending patients into remission than a standard oral drug called ...

Spravato, a nasal spray esketamine, was found to work better than Seroquel for treatment-resistant depression, a study in the New England Journal of Medicine finds.

A new study finds an esketamine nasal spray achieved remission and prevented relapse of depression in patients with treatment-resistant depression.

Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in treatment-resistant depression, a study found.